Optimas Capital’s Medtronic MDT Stock Holding History

Optimas Capital’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-32,650	Closed	-$3.62M	–	30
2022 Q1	$3.62M	Buy	+32,650	New	+$3.45M	3.4%	15

Other funds holding MDT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Optimas Capital's MDT Position: Q2 2022 in Review

Optimas Capital sold out of Medtronic (MDT) in Q2 2022, closing a stake of 32,650 shares — an estimated $3.62M sold.

Optimas Capital first reported a position in MDT in Q1 2022 and held it in 1 quarter. The position peaked at $3.62M in Q1 2022. 2,023 funds tracked by Wall St. Rank hold MDT as of Q2 2022.

Optimas Capital reported no remaining Medtronic position as of Q2 2022 after selling out during the quarter.
Optimas Capital sold 32,650 Medtronic shares in Q2 2022, an estimated $3.62M.
Optimas Capital first reported a position in Medtronic in Q1 2022 and held it in 1 quarter.
Optimas Capital's Medtronic position peaked at $3.62M in Q1 2022.
2,023 funds tracked by Wall St. Rank held Medtronic as of Q2 2022.

Based on Optimas Capital's 13F filing for Q2 2022, filed 12 Aug 2022.